Phase 2 N=15 LMB-2 to Treat Hairy Cell Leukemia
Hairy Cell Leukemia
Primary: Number of Patients Who Obtain Partial Response/Complete Remission — 1; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=36 BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Hairy Cell Leukemia
Primary: Efficacy of Vemurafenib — 10; 14; 12 Participants
Phase 1 N=49 A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia
Hairy Cell Leukemia
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 3 N=80 Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Leukemia, Hairy Cell
Primary: Percentage of Participants With Durable Complete Response (CR) Assessed by Blinded Independent Central Review — 36.3 Percentage of participants
Phase 2 N=29 Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
T-LGL Lymphoproliferative Disorders
Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants
Phase 2 N=15 Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
Leukemia · Lymphocytic · Chronic
Primary: Response Rate — 0; 1; 3; 11 Participants
Phase 2 N=29 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma
Acute T-Cell Leukemia-Lymphoma
Primary: Overall Response Rate — 52 percentage of participants
Phase 2 N=105 Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
Chronic Lymphocytic Leukemia
Primary: Change in Gene Expression Post Chemo — 30; 50 Percent change in cells
Phase 2 N=102 Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
Leukemia
Primary: Response Rate — 55.2 percentage
Phase 2 N=33 Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
Leukemia
Primary: Number of Confirmed Responses (Complete or Partial Response Noted as the Objective Status for a Duration of at Least 2 Months) at 6 Months — 31 Participants
Phase 2 N=60 CFAR Study in Patients With Chronic Lymphocytic Leukemia
Leukemia · Chronic Lymphocytic Leukemia
Primary: Overall Participant Response — 44; 1; 10 Participants
Phase 2 N=18 Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
Adult T-Cell Leukemia (ATL)
Primary: Percentage of Participants With a Minimally Durable Clinical Response Rate — 80; 0; 60; 0 percentage of participants
Phase 2 N=1 Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Untreated Chronic Lymphocytic Leukemia
Primary: Participants With a Clinical Response — 0 Participants
Phase 2 N=22 Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Refractory Chronic Lymphocytic Leukemia · Stage 0 Chronic Lymphocytic Leukemia
Primary: Maximum Tolerated Dose (MTD) of PGG Beta Glucan in Combination With Alemtuzumab and Rituximab Assessed by Analyzing the Number of Dose-limiting Toxicity Events (Phase I)…
Phase 2 N=4 Lenalidomide in HTLV-1 Adult T-Cell Leukemia
Adult T Cell Leukemia/Lymphoma
Primary: Response Rate (CR + Cru + PR)
Phase 2 N=43 Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
Leukemia
Primary: Overall Responders (Complete and Partial Response) — 8; 18 participants
Phase 2 N=41 Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia · Lymphoma
Primary: Complete Response Rate — 10 percentage of participants
Phase 2 N=102 Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia
Primary: Number of Participants With a Complete Response After Treatment With Fludarabine & Rituximab Followed by Alemtuzumab — 38 participants
Phase 2 N=80 Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Number of Participants With an Overall Response — 23; 3; 26 Participants
Phase 2 N=60 Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Complete Response (CR) — 8.3 Percentage of participants with CR — p=0.014
Phase 2 N=23 Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic · Chronic Lymphocytic Leukemia · Small Lymphocytic Leukemia
Primary: Participants With Complete Remission (CR) at 24 Months — 3 Participants
Phase 2 N=44 Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia · Lymphoma
Primary: Number of Participants With Complete Response (CR) — 14 participants
Phase 2 N=49 Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Leukemia · Lymphoma
Primary: Overall Objective Response — 10; 5; 26; 4 Participants
Phase 3 N=817 Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
Leukemia
Primary: Progression-free Survival (PFS) — 981.0; 1212.0 Days — p=<.0001
Phase 2 N=43 CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Primary Mediastinal B-cell Lymphoma · Diffuse, Large B-cell Lymphoma · Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma
Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants
Phase 2 N=50 Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
Leukemia · Lymphoma
Primary: Overall Response — 11; 23; 4; 5 participants
Phase 2 N=60 FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Participant Overall Response Rate (ORR) at 6 Months Includes Complete Remissions, Partial Remission, or Nodule Partial Remissions. — 100 Percentage of Participants
Phase 2 N=10 Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas
Lymphoma · T-Cell · Cutaneous
Primary: Response Rate — 0; 0; 1; 1 Participants
Phase 2 N=3 Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Acute Adult T-Cell Leukemia/Lymphoma · Adult T-Cell Leukemia/Lymphoma · Chronic Adult T-Cell Leukemia/Lymphoma
Primary: Incidence of Adverse Events of Nivolumab, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 3 Participants
Phase 2 N=35 Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy
Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia · Stage III Chronic Lymphocytic Leukemia
Primary: Rate of Confirmed MRD-negative Response — 0 proportion of patients